Market Update (NASDAQ:GILD): Gilead shares dip after warning about hepatitis C drug interaction

[Reuters] – Gilead Sciences Inc shares slid 2 percent on Monday after the company warned about potentially fatal risks for patients being treated with its top-selling hepatitis c drugs who also take the . . . → Read More: Market Update (NASDAQ:GILD): Gilead shares dip after warning about hepatitis C drug interaction Similar Articles: Company Update (NASDAQ:GILD): CORRECTED (OFFICIAL)-UPDATE 1-Aetna backs Gilead’s hepatitis C treatment, gets discount Market Update (NASDAQ:GILD): UPDATE 1-Anthem selects Gilead as primary supplier of hepatitis C drugs Company Update: Gilead Sciences Inc (NASDAQ:GILD) – U.S. FDA approves Gilead’s $94,500 hepatitis C drug